Fibrinogen Concentrate - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The fibrinogen concentrate market size is expected to increase from USD 1.34 billion in 2025 to USD 1.43 billion in 2026 and reach USD 1.95 billion by 2031, growing at a CAGR of 6.46% over 2026-2031. This report is Segmented by Source (Human Plasma-Derived Concentrates, Recombinant/Synthetic Analogues), Application (Congenital Fibrinogen Deficiency, Trauma & Surgery-Related Hemorrhage, and More), End User (Hospitals, and More), Form (Lyophilized Powder Vials, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Fibrinogen Concentrate Market Trends and Insights

Growing Diagnosis of Congenital & Acquired Bleeding Disorders

Rare-bleeding-disorder registries and next-generation sequencing panels make FGA, FGB, and FGG variant detection routine, shrinking the diagnostic gap for fewer than two patients per million affected by congenital fibrinogen loss. Consumption coagulopathy in trauma, obstetrics, and liver disease drives acquired deficiency episodes, prompting Ontario’s March 2025 Major Hemorrhage Protocol to replace cryoprecipitate with a 4-gram fibrinogen bolus. Australia followed in September 2025 with guideline revisions that set a 2 g/L threshold for concentrate use. Collectively, these moves institutionalize fibrinogen concentrate within goal-directed transfusion bundles, reduce product thaw time, and standardize dosing. Improved diagnosis expands the potential treated population, reinforcing market momentum.

Regulatory Shift from Cryoprecipitate to Virally-Inactivated Concentrates

FDA clearance of Octapharma’s Fibryga for acquired deficiency in September 2024, anchored by the 735-patient FIBRES trial, signaled U.S. endorsement of standardized concentrates over variable cryoprecipitate. Ireland, the United Kingdom, and Canada quickly embedded concentrates into national transfusion protocols, with the United Kingdom awarding a GBP 1.168 billion tender in February 2024 that ring-fenced Lot 18 exclusively for fibrinogen concentrate. These policy shifts shorten thaw-to-administration times, lower pathogen-transmission risk, and create predictable demand that encourages capacity expansion by fractionators.

High Therapy Cost & Uneven Reimbursement

A standard 4-gram dose costs USD 2,000-4,000, a hurdle for hospitals in lower-income regions. Cost-effectiveness analysis from the Canadian FIBRES trial showed median 7-day all-blood-product costs of USD 1,697 for concentrate versus USD 2,063 for cryoprecipitate, yet payer coverage still varies. Anthem’s March 2025 policy added Fibryga under HCPCS J7177, but some Medicaid plans label concentrate investigational for dysfibrinogenemia, limiting access. Static CMS furnishing fees fail to offset hospital acquisition inflation, particularly in safety-net facilities. The reimbursement mosaic slows uptake outside premium health systems.

Other drivers and restraints analyzed in the detailed report include:

• Capacity Expansion of Plasma-Fractionators in Emerging Markets
• Shelf-Stable Heat-Tolerant Formulations for Battlefield & Aerospace Kits
• Thrombotic-Event Pharmacovigilance Burden

Segment Analysis

Human plasma-derived products captured 75.54% of 2025 revenue, anchoring the fibrinogen concentrate market share with well-entrenched brands such as RiaSTAP, Fibryga, and Fesilty. Takeda’s USD 230 million Los Angeles upgrade underscores ongoing investment to secure plasma inputs. The fibrinogen concentrate market size for plasma products is projected to grow steadily as new collection centers open, yet its CAGR lags the 12.25% pace forecast for recombinant entrants.

Recombinant and synthetic formats, although nascent, promise supply independence and zero pathogen risk. The RECOFIB consortium’s 1 g/L milestone advances commercial viability, and venture funding accelerates bioprocess optimization. Cost parity and regulatory equivalence remain hurdles; however, once achieved they can erode plasma dominance. Over the forecast horizon, incremental penetration by recombinant platforms will diversify sourcing and mitigate supply shocks, reshaping competitive dynamics within the fibrinogen concentrate market.

Trauma and surgical hemorrhage commanded 46.54% of the fibrinogen concentrate market size in 2025 as massive-transfusion bundles mandate immediate fibrinogen replacement. Viscoelastic testing ensures dose precision, curbing wastage and reinforcing hospital adoption. Obstetric bleeding is set to lead growth at a 12.65% CAGR, lifted by WHO 2025 guidance that endorses concentrate over cryoprecipitate for postpartum hemorrhage.

The fibrinogen concentrate market share linked to congenital deficiency remains niche but sustained by new FDA-approved indications that provide prophylactic paradigms. Off-label cardiac and hepatic surgery usage rounds out the application mix, and emerging evidence from ongoing real-world registries is likely to broaden labeled claims, supporting further incremental adoption across specialties.

Complete Report Scope:

• By Source
  • Human Plasma-derived Concentrates
  • Recombinant / Synthetic Analogues
• By Application
  • Congenital Fibrinogen Deficiency
  • Trauma & Surgery-related Haemorrhage
  • Obstetric & Gynaecological Bleeding
  • Others (Intracranial, Cardiac, etc.)
• By End User
  • Hospitals
  • Specialty Clinics & Haemophilia Centres
  • Military & EMS
• By Form
  • Lyophilised Powder Vials
  • Ready-to-use Liquid Formulations
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led with 37.53% of 2025 revenue thanks to early regulatory approvals, payer coverage under HCPCS J7177, and widespread viscoelastic testing infrastructure. The United States alone accounts for more than 70% of regional demand as new indications widen the addressable pool, while Canada’s national blood strategy cements concentrate use in major trauma. Mexico remains entirely import-reliant, but formulary inclusion discussions are underway.

Asia-Pacific posts the fastest forecast CAGR at 10.1%, propelled by China’s plasma-fractionation modernization and India’s capacity scale-up. Japan and South Korea maintain self-sufficient fractionation ecosystems that prioritize high-purity products, whereas Southeast Asian markets still depend on multilateral procurement donors for supply continuity. Upward revisions to postpartum hemorrhage protocols in Australia further stimulate regional uptake.

Europe’s fragmented reimbursement keeps growth moderate. Northern and Western states adopt concentrates rapidly via centralized tenders, but Southern and Eastern regions face budget constraints. LFB’s EUR 500 million capacity build aims to cut U.S. plasma dependence and could smooth future supply. The Middle East and Africa rely on imports, with Gulf Cooperation Council militaries driving niche demand for shelf-stable formats. Latin America lags as reimbursement hurdles and cold-chain limits slow substitution of cryoprecipitate.

List of Companies Covered in this Report:

• Bharat Serums & Vaccines
• Bio Products Laboratory (BPL)
• Biotest
• CSL Behring
• GC Pharma (Green Cross)
• Grifols Biotherapeutics (Fesilty)
• Grifols
• Hualan Biological Engineering
• Intas Pharmaceuticals
• Jiangxi Boya Biological
• Kedrion Biopharma
• LFB S.A.
• Octapharma
• Prothya Biosolutions
• Sanquin Plasma Products
• Shanghai RAAS Blood Products
• Sinopharm (CNPGC)
• Takeda Pharmaceutical Co.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support